Jun O. Liu

Jun O. Liu

Auto-generated profile, based on publicly available information

Jun O. Liu

Center for Cancer Research, Departments of Biology and Chemistry, Massachusetts Institute of Technology, Cambridge, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 1996 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ELEdward J. Licitra
Edward J. Licitra
JLJun O. Liu
Jun O. Liu
Small ligand–receptor interactions underlie many fundamental processes in biology and form the basis for pharmacological intervention of human diseases in medicine. We report herein a genetic system, named the yeast three-hybrid system, for detecting ligand–receptor interactions in vivo . This system is adapted from the yeast two-hybrid system with which a third synthetic hybrid ligand is combined. The feasibility of this system was demonstrated using as the hybrid ligand a heterodimer of covalently linked dexamethasone and FK506. Yeast expressing fusion proteins of the hormone binding domain of the rat glucocorticoid receptor fused to the LexA DNA-binding domain and of FKBP12 fused to a transcriptional activation domain activated reporter genes when plated on medium containing the dexamethasone–FK506 heterodimer. The reporter gene activation is completely abrogated in a competitive manner by the presence of excess FK506. Using this system, we screened a Jurkat cDNA library fused to the transcriptional activation domain in yeast expressing the hormone binding domain of rat glucocorticoid receptor–LexA DNA binding domain fusion protein in the presence of dexamethasone–FK506 heterodimer. We isolated overlapping clones of human FKBP12. These results demonstrate that the three-hybrid system can be used to discover receptors for small ligands and to screen for new ligands to known receptors.

22 December 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EGEric C. Griffith
Eric C. Griffith
ZSZhuang Su
Zhuang Su
Satomi NiwayamaSatomi Niwayama
Satomi Niwayama
CRCameron A. Ramsay
Cameron A. Ramsay
Yie-Hwa ChangYie-Hwa Chang
Yie-Hwa Chang
JLJun O. Liu
Jun O. Liu
Angiogenesis inhibitors are a novel class of promising therapeutic agents for treating cancer and other human diseases. Fumagillin and ovalicin compose a class of structurally related natural products that potently inhibit angiogenesis by blocking endothelial cell proliferation. A synthetic analog of fumagillin, TNP-470, is currently undergoing clinical trials for treatment of a variety of cancers. A common target for fumagillin and ovalicin recently was identified as the type 2 methionine aminopeptidase (MetAP2). These natural products bind MetAP2 covalently, inhibiting its enzymatic activity. The specificity of this binding is underscored by the lack of inhibition of the closely related type 1 enzyme, MetAP1. The molecular basis of the high affinity and specificity of these inhibitors for MetAP2 has remained undiscovered. To determine the structural elements of these inhibitors and MetAP2 that are involved in this interaction, we synthesized fumagillin analogs in which each of the potentially reactive epoxide groups was removed either individually or in combination. We found that the ring epoxide in fumagillin is involved in the covalent modification of MetAP2, whereas the side chain epoxide group is dispensable. By using a fumagillin analog tagged with fluorescein, His-231 in MetAP2 was identified as the residue that is covalently modified by fumagillin. Site-directed mutagenesis of His-231 demonstrated its importance for the catalytic activity of MetAP2 and confirmed that the same residue is covalently modified by fumagillin. These results, in agreement with a recent structural study, suggest that fumagillin and ovalicin inhibit MetAP2 by irreversible blockage of the active site.

15 August 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
HYHong‐Duk Youn
Hong‐Duk Youn
TCTalal A. Chatila
Talal A. Chatila
JLJun O. Liu
Jun O. Liu
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

6 June 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YZYi Zhang
Yi Zhang
EGEric C. Griffith
Eric C. Griffith
JSJulien Sage
Julien Sage
TJTyler Jacks
Tyler Jacks
JLJun O. Liu
Jun O. Liu
Angiogenesis has been demonstrated to be essential for tumor growth and metastasis, and inhibition of angiogenesis is emerging as a promising strategy for treating cancer. Among the most potent inhibitors of angiogenesis is the fumagillin family of natural products. An analog of fumagillin, known as TNP-470 or AGM-1470, has been undergoing clinical trials for treating a variety of cancers. TNP-470 has been shown to block endothelial cell cycle progression in the late G 1 phase. Although the direct molecular target for TNP-470 has been identified as the type 2 methionine aminopeptidase (MetAP2), how inhibition of this enzyme leads to cell cycle arrest has remained unclear. We report that treatment of endothelial and other drug-sensitive cell types leads to the activation of the p53 pathway, causing an accumulation of the G 1 cyclin-dependent kinase inhibitor p21 WAF1/CIP1 . The requirement of p53 and p21 WAF1/CIP1 for the cell cycle inhibition by TNP-470 is underscored by the observation that cells deficient in p53 and p21 WAF1/CIP1 are resistant to TNP-470. These results shed significant light on the mechanism of cell cycle inhibition by TNP-470 and suggest an alternative method of activating p53 in endothelial cells to halt angiogenesis and tumor progression.

1 October 2003
Verified
Journal Article
Closed access
HKHyungsoo Kim
Hyungsoo Kim
JLJi-Eun Lee
Ji-Eun Lee
ECEun-Jung Cho
Eun-Jung Cho
JLJun O Liu
Jun O Liu
HYHong-Duk Youn
Hong-Duk Youn

16 May 2001 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
WLWeifeng Liu
Weifeng Liu
HYHong-Duk Youn
Hong-Duk Youn
JLJun O. Liu
Jun O. Liu
Thapsigargin (TG), which inhibits endoplasmic reticulum‐dependent Ca2 +‐ATPase and thereby increases cytosolic Ca2 +, has been reported to cause apoptosis in T lymphocytes another cell types. In this study, we investigated the molecular mechanisms that are involved in the apoptosis induced by TG in T cell hybridomas. Exposure to TG results in rapid induction of the orphan steroid receptor, Nur77, accompanied by apoptosis of T cell hybridomas. The expression of Nur77 in response to TG treatment is sensitive to cyclospo‐rin A, implicating that activation of calcineurin is necessary for Nur77 expression. The TG‐induced Nur77 expression is also inhibited by overexpression of Cabin1, an endogenous inhibitor of calcineurin and a corepressor of the transcription factor MEF2, suggesting that MEF2 activation is required for Nur77 expression. These results suggest that induction of Nur77 expression and apoptosis by TG are mediated by the same signaling pathwaysthat are involved in T cell receptor‐mediated thymocyte apoptosis, including the calcineurin pathway and Cabin1‐MEF2 pathway.